Abstract: Animal protein-free, solid-form Clostridial toxin pharmaceutical compositions comprising a Clostridial toxin active ingredient and at least two excipients.

Abstract: Preparations and formulations capable of crossing and incorporating into a membrane of a cell or an organelle or an exosome are described. Methods of treatments utilizing the preparations and formulations are also described.

Abstract: A nucleic acid film fabrication method, includes: a mixing step in which a nucleic acid is added in powder form to distilled water or deionized water to prepare a mixed solution; a stirring step in which the mixed solution is stirred; a mixed solution application step in which the mixed solution is applied to a mold corresponding in shape to a final product of a nucleic acid film; and a drying step in which the mixed solution applied to the mold is dried to be formed into the nucleic acid film, wherein the mold has a groove formed thereon in a thickness direction thereof, such that the nucleic acid film passing through the drying step has a protrusion protruding from one surface thereof toward human skin to correspond to the groove.

Abstract: A composition for the delayed delivery of a peptide active agent comprising; i) a salt of said peptide active agent comprising at least one positively charged peptide ion and at least one negatively charged counter-ion ii) a sustained-release delivery vehicle, wherein the at least one negatively charged counter-ion is a halide ion, preferably a chloride or bromide ion.

Abstract: The object of the present invention is to provide a technique for promoting membrane permeation of a drug, which is highly versatile and highly safe. The object can be solved by a polymer compound having a molecular weight of 1000 or more, wherein the polymer compound has, at an end of a side chain, one arginine or a basic peptide of chain length of 2 to 6 containing one or more arginine, and comprises a guanidino group of 0.5 to 20 mmol/g, originating from arginine.

Abstract: Provided herein include formulations for topical administration, such as ophthalmic formulations, and methods of using such formulations. In some aspects and embodiments the formulations may include a polyoxyl lipid or fatty acid, and/or a polyalkoxylated alcohol and may include nanomicelles. Also include methods of treating or preventing diseases or conditions, such as ocular diseases or conditions.

Abstract: The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, as well as methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a disclosed lipid prodrug or a pharmaceutical composition thereof.

Abstract: This disclosure provides novel saccharide derivatives, conjugates, and methods for making the derivatives and conjugates.

Abstract: Methods are provided for producing a PEGylated interleukin 11 (IL-11) tby treating a recombinant IL-11 PEGylated with an equimolar to low molar excess of PEG carrying an amine-reactive group to achieve a highly pure monoconjugate preparation, which provides improved half-life in serum while having desirable therapeutic activity and presenting fewer side-effects. Most preferably, the IL-11 is an N-terminally truncated human or humanized IL-11 and has a 20 Kd or 40 Kd branched PEG moiety, Y- or comb-shaped in particular, coupled to the N-terminal amino group. Such compounds are characterized by substantially increased stability in serum and sustained biological activity while exhibiting significantly reduced plasma expansion.

Abstract: Iron carbohydrate complex for treatment of fetal metal deficiency Disclosed herein is a pharmaceutical composition comprising an iron carbohydrate complex for use in a method for treatment or prevention of an iron deficiency of a fetus or an infant, wherein the iron carbohydrate complex is administered to the mother of the fetus or infant.

Abstract: A pharmaceutical composition is described, essentially consisting of the paclitaxel prodrug associated with pharmacologically acceptable diluents/excipients, for use in the treatment of non-muscle invasive bladder cancer (NMIBC) by means of intravesical instillations according to a single weekly dose of 600 mg of said prodrug, or two weekly doses equal to a total of 1,200 mg, for 12 or 6 consecutive weeks of treatment. The paclitaxel prodrug used was prepared according to an indirect synthesis process between molecules of hyaluronic acid (HA) and paclitaxel by introducing a spacer (4-bromobutyric acid) between the hyaluronic acid and chemotherapeutic agent.

Abstract: Described herein are methods and compositions for nerve delivery molecules that carry imaging cargo or therapeutic cargo to the neurons or nerves.

Abstract: Methods for producing engineered exosomes and other vesicle-like biological targets, including allowing a target vesicle-like structure to react and bind with immunomagnetic particles; capturing the immunomagnetic particle/vesicle complex by applying a magnetic field; further engineering the captured vesicles by surface modifying with additional active moieties or internally loading with active agents; and releasing the engineered vesicle-like structures, such as by photolytically cleaving a linkage between the particle and engineered vesicle-like structures, thereby releasing intact vesicle-like structures which can act as delivery vehicles for therapeutic treatments.

Abstract: Two disparate biological mechanisms which predispose to the dissemination and metastases of solid tumors is described.

Abstract: A conjugate comprising at least one calcineurin phosphatase inhibitor and a nanodiamond.

Abstract: A combination therapy involving different therapeutic molecules can enhance and improve the therapeutic potentials. An effective therapeutic strategy conjugates silica (SiO2) nanoparticles with, e.g., 3-glycidyloxypropyl, trimethoxysilane and azoles, e.g., 1,2,4-triazole (Tri), 3-aminotriazole (ATri), 5-aminetetrazole (Atet), imidazole (Imi). These exemplary materials—classified as SiO2-3GPS-Tri (Conj. 1), SiO2-3GPS-Atri (Conj. 2), SiO2-3GPS-Atet (Conj. 3), SiO2-3GPS-Btri (Conj. 4), and SiO2-3GPS-Imi (Conj. 5)—can amplify targeting of therapeutics for human colorectal carcinoma cells (HCT-116), enhancing anti-cancer effects.

Abstract: Several new vector-promoter combinations to overcome the limitations associated with AAV-mediated cone transduction in the fovea are provided. The delivery modality relies on a cone-specific promoter and result in high-level transgene expression compatible with optogenetic vision restoration. Methods of expressing a polynucleotide of interest in the cone photoreceptors of a subject comprising subretinal delivery of a therapeutically effective amount of a recombinant AAV9-derived vector comprising a VP1 capsid protein as set forth in SEQ ID NO: 11 and the polynucleotide of interest under the control of the pR1.7 promoter as set forth in SEQ ID NO: 12 are also provided.

Abstract: Methods for treating a neurological disorder, such as a traumatic spinal cord injury or traumatic brain injury, or a disorder such as Parkinson's disease or multiple sclerosis are provided. Such methods include administering a therapeutically effective amount of Gsx1 protein (such as a Gsx1-cell penetrating peptide fusion protein), or a nucleic acid molecule encoding such a protein (for example as part of a viral vector), thereby treating the neurological disorder.

Abstract: The various embodiments relate to the identification of non-viable tissue for debridement using a pH low insertion peptide conjugate. pH low insertion peptide conjugates are described having fluorescent dye for introduction to the wound area. The peptides may further be conjugated with a drug for introduction to the tissue.

Abstract: Biodegradable fluorescent silica nanoparticle (FSN) are provided for in vivo imaging, particularly of cancerous and precancerous lesions in the gastrointestinal tract. The FSN are comprised of (a) a dye that fluoresces in the near infrared spectrum which is (i) covalently joined to a silane, and (ii) distributed throughout the nanoparticle; and (b) silica distributed throughout the nanoparticle. The surface may be coated with hydroxyl-terminated PEG, which is shown to reduce uptake of the nanoparticles by the liver. The dyes provide for sensitive detection of clinically relevant lesions, and are biodegradable.

Abstract: A nanoparticle includes a nanocarrier encapsulating a nanoscintillator capable of emitting light upon exposure to radiation; a photosensitizer capable of absorbing the light from the nanoscintillator to generate singlet oxygen species; and optionally, one or more diagnostic agents, therapeutic agents, or a combination thereof.

Abstract: Provided herein are improved methods for preparing phospholipid formulations including phospholipid UCA formulations.

Abstract: The present invention relates to a kit for radiolabelling a targeting agent with gallium-68. The present invention also relates to the use of said kit for radiolabelling a targeting agent, a method for radiolabelling a targeting agent with gallium-68 using said kit, said kit and a method of preparation.

Abstract: Provided herein are methods of sequestering target elements (e.g., rare earth elements and/or radiometals) from a sample, methods of purifying target elements from samples, pharmaceutical compositions comprising target elements, and methods of treating a subject with said pharmaceutical compositions.

Abstract: Provided is an apparatus for treating a surface of a medical metal. The apparatus includes a lamp unit in which a through-hole is formed and which irradiates the through-hole with ultraviolet rays, a lifting unit on which a container accommodating a medical metal is detachably disposed and which is disposed to be movable in the through-hole, and a case unit which accommodates the lamp unit and the lifting unit and includes an outer case in which an outer hole corresponding to the through-hole is formed and an inner case which is disposed inside the outer case and in which the lamp unit or the lifting unit is disposed.

Abstract: Sterilizing devices, preferably foot mats, comprise: a support member having an arrangement structure and a plurality of UV light emitting members, where the support member is configured for total internal reflection of UV light from the UV light emitting members; a power source providing power to the plurality of UV light emitting members; and a translucent substrate having an upper surface and a lower surface; wherein the translucent substrate is disposed above the support member such that the lower surface of the translucent substrate can be brought into contact with an upper region of the support member when a downward force is applied to the upper surface of the translucent substrate; and wherein the contact between the lower surface of the translucent substrate and the support member breaks the total internal reflection in the area of contact such that UV light is emitted through the translucent substrate.

Abstract: Disclosed herein are methods of disrupting cell-to-cell communication. An exemplary method comprises transmitting one or more microwave signals to a communication molecule located in an environment having a plurality of cells. The one or more microwave signals can comprise a first microwave signal and a second microwave signal. The first microwave signal can have a first frequency corresponding to frequency of a first peak in a microwave spectrum associated with rotational modes of the communication molecule. The second microwave signal can have a second frequency corresponding to a frequency of a second peak in the microwave spectrum associated with the rotational modes of the communication molecule.

Abstract: A process for sanitizing and/or disinfecting porous and solid surfaces and airborne particles in ambient air by killing bacteria and viruses, including the steps of: providing an enclosed water storage tank having a predetermined maximum water surface level, generating ultrasonically with an ultrasonic oscillator mounted slightly below the water level in the water storage tank, a dry mist that is forced into a blending chamber above said water level in said water storage tank; an air blower with an airflow outlet connected into said water storage tank, and above the tank maximum water level, and an ozone generator outlet connected into said water storage tank for providing a predetermined amount of ozone, above the water level, into the water storage tank during operation, creating an ozone-saturated dry mist. The ozone dissolves in the dry mist and forms a saturated or super-saturated dry mist created in the water storage tank.

Abstract: A sterile container unit for receiving items which are sterilized or are to be sterilized includes a container tray and a container lid that can be coupled to the container tray by a closure element. The closure element can be actuated by a pivoting movement. An information carrier can be interlockingly fastened to the container tray and set up to display information regarding the content of the sterile container unit. The container tray, the closure element and the information carrier are adapted to one another such that, following the pivoting movement of the closure element, the information carrier is rigidly fixed/locked on the container tray.

Abstract: A scent-masking mixture and method for making and using that mixture are disclosed. That scent masking mixture includes an “Earth Scent” fragrance, Eucalyptus essence, peppermint essence, rosemary essence, clove essence, and water. The majority of the scent-masking mixture may be water while the largest amount of active ingredient might be the “Earth Scent” fragrance. The scent-masking mixture beneficially includes equal amounts of Eucalyptus essence and rosemary essence. Preferably there is more peppermint essence than clove essence.

Abstract: The present invention relates to a sodium polyacrylate super absorbent resin for blood absorption with a gradual hierarchical structure. When a blood simulant solution is used as the detection medium, according to ISO 19699-1:2017(E), the absorption capacity of the blood simulant solution is ?18.0 g/g, Preferably ?18.5 g/g; the absorption rate of the blood simulant solution is ?45 s, preferably ?40 s, more preferably ?38 s; when human blood is used as the detection medium, according to ISO 19699-1:2017(E), the absorption capacity of the human blood is ?8.0 g/g, preferably ?8.3 g/g, more preferably ?8.6 g/g; the absorption rate of the human blood is ?45 s, preferably ?40 s, more preferably ?35 s, most preferably ?25 s.

Abstract: Methods for forming and incorporating microparticles containing one or more active agents into adhesives are described. The methods involve spray drying a liquid of the one or more active agents and obtaining the active agent in a particulate form. The dry powder is then blended or otherwise incorporated with the adhesive of interest. Also described are various medical products utilizing the adhesive and one or more active agents in microparticle form, and related methods of use.

Abstract: Methods are provided for making freeze dried hydrogel and structures therefrom that may be introduced into a patient's body for medical applications. Precursor components are combined to initiate crosslinking. The combined precursor components are placed in a chilled tray, and allowed to crosslink to a desired level of complete crosslinking before and/or after being placed onto the tray. The partially crosslinked hydrogel is frozen and freeze dried. After freeze drying, the hydrogel is conditioned to substantially complete crosslinking, and formed into one or more structures, e.g., plugs, hemostatic, or other medical devices. For example, the hydrogel may be cut, machined, rolled, folded, compressed, and/or cored into that may be loaded into delivery devices that may be introduced into a body to implant or otherwise deliver the structures into the body, e.g., to seal a puncture or other passage through tissue.

Abstract: Disclosed is a moisture switchable adhesive composition including a polymer and a switch initiator. The composition can be switched from a first liquid state to a second adhesive state by activation of the switch initiator. The composition has in the first liquid state a complex viscosity |?*| below 0.4 MPa s; and the composition has in the second adhesive state a second repeated peel force above 1 N/25 mm.

Abstract: The hyaluronic acid filler according to the present invention exhibits improved high viscoelastic flow characteristics, and has advantages of monophasic hyaluronic acid fillers and biphasic hyaluronic acid fillers together, and therefore it maintains the shape while having low moving possibility when injecting into skin, and thus it is excellent when used for improving wrinkles, augmentation of soft tissues such as cheeks, breast, nose, lips and hips, etc., and correcting contours, and the duration time in the human body is increased and side effects are small, even if a small amount of crosslinking agent is used during the preparation process.

Abstract: Disclosed herein are safe and effective ways to perform dermal filling procedures. Specifically, the present disclosure relates to agarose-based dermal fillers with advanced rheological properties which are easier to inject and disperse compared to HA based dermal fillers. The present disclosure further relates to the methods and kits to provide additional safety advantages over other injectables, as the agarose-based dermal fillers can be dispersed quickly to prevent injury to a patient.

Abstract: A medical device for implantation in tissue includes: a header including one or more bores, the header including an implant grade thermoplastic resin including a conductive additive and a metal coating; one or more leads disposed in the header and exiting the header through the one or more bores; and an enclosure coupled to the header at a surface of the enclosure, the enclosure including circuitry and a power source. A sterilized header for an implantable enclosure is also described.

Abstract: The invention relates to a coating for implantable medical devices. The coating contains a layer complex which comprises at least one polyelectrolyte multilayer and at least one layer of functionalized nanodiamonds. The at least one polyelectrolyte multilayer consists of polyelectrolyte monolayers which are charged positively and negatively in an alternating manner. Additionally, the functionalized nanodiamonds are functionalized with at least one bioactive agent. The invention additionally relates to a method for producing such a coating for implantable medical devices, to the use of such a coating, and to an implantable medical device which has such a coating.

Abstract: The present invention provides demineralized bone fibers exhibiting optimal handling properties (e.g., high moldability and low elastic modulus) and biological activities (e.g., osteoinductivity) as well as non-demineralized bone fibers useful for preparing the demineralized bone fibers. A well-controlled demineralization process for preparing the demineralized bone of fibers is also provided. Products comprising the demineralized bone fibers and uses thereof are further provided.

Abstract: Methods are disclosed for dissecting a mucosa and a submucosa from a muscularis propria from a region of the esophagus of a subject. These methods include injecting submucosally into the region of the esophagus of the subject a pharmaceutical composition comprising a urinary bladder extracellular matrix (ECM) hydrogel, to form a cushion between the submucosa and the underlying muscularis propria at the region of the esophagus, wherein the ECM hydrogel has the following characteristics: a) a time to 50% gelation of less than 20 minutes at a temperature of about 37° C.; b) a flow viscosity suitable for infusion into the esophagus; and c) a stiffness of about 10 to about 400 Pascal (Pa).

Abstract: A differential tissue-engineered nerve including motor-like nerves and sensory-like nerves. The motor-like nerve and the sensory-like nerve respectively includes a motor-like nerve outer tube and a motor-like nerve fiber in the outer tube as well as a sensory-like nerve outer tube and a sensory-like nerve fiber in the outer tube. Schwann cells and/or fibroblasts derived from motor nerves and sensory nerves are respectively contained in surfaces or pores of the motor-like and sensory-like nerve outer tubes. Transsynaptic signal molecules Neuroligin-1 and Neuroligin-2 are contained in surfaces or pores of the motor-like and sensory-like nerve fibers. Neuroligin-1 is selectively used to specifically promote synaptic remodeling of motor neurons, while Neuroligin-2 is selectively used to specifically promote synaptic remodeling of sensory neurons, so that repair efficiency of motor nerve cells and sensory nerve cells is improved.

Abstract: The method for decellularization of kidney tissue according to the present invention, the decellularized material produced through the method, and a bioink comprising the decellularized material have the effect of maximizing the effect of kidney treatment by maximizing the content of components specialized for kidney treatment such as the collecting duct and renal tubule of the kidney.

Abstract: A pre-loadable biological heart valve capable of rapid rehydration and a preparation method thereof. The preparation method comprises a cross-linking treatment, wherein a biological valve is cross-linked by soaking in an aqueous glutaraldehyde solution; a hydrophilic treatment, wherein the biological valve is soaked in a solution containing a hydrophilic molecule and a condensing agent, to allow the hydrophilic molecule to be immobilized on the biological valve by chemical grafting; and a drying treatment, wherein the biological valve after the hydrophilic treatment and the cross-linking treatment is dried to obtain a pre-loadable biological heart valve capable of rapid rehydration. The pre-loadable biological heart valve prepared by the preparation method of the present disclosure achieves rapid rehydration, and the crease can be quickly flattened after rehydration, bringing convenience during use.

Abstract: The present disclosure relates to a biocompatible, electrically conductive membrane capable of carrying the electrical potential of a cardiac impulse. The present disclosure also relates to treatments using the electrically conductive polymer, such as for atrial fibrillation.

Abstract: A bioprosthetic valve for repairing a deep venous insufficiency in a subject includes a single leaflet from a xenogeneic heart valve attached at natural margins of attachment to a patch of valve wall tissue. The patch may extend axially above and below the leaflet and circumferentially on either side of the leaflet to provide a region for attaching the patch to a fenestration in a host vein. A bioprosthetic valve may be manufactured by excising a portion of a xenogeneic heart valve including a single leaflet and contiguous wall tissue, and may further comprise shaving off excess leaflet tissue from adjacent leaflets. A method of replacing a malfunctioning venous valve in a subject includes providing a bioprosthetic valve as described above and inserting it to the host vein.

Abstract: Three dimensional nanofiber structures are provided and methods of production thereof.

Abstract: A medical system including a tube defining a lumen, a porous body connected to a distal end of the tube to be advanced to a target site within a subject. The porous body defines a plurality of openings, the plurality of openings are in fluid connection with the lumen, the porous body includes a first material and a second material, and the second material elutes from the porous body in the subject.

Abstract: Described herein are nitric oxide releasing materials, methods of making nitric oxide releasing materials, and devices including nitric oxide releasing materials. The nitric oxide releasing material includes a polymer matrix having a plurality of polysiloxanes and nitric oxide-donating crosslinking moieties that covalently crosslink the polysiloxanes. Blood clotting or adhesion of a bio-material to a surface, as well as biofilm formation can be prevented using the methods and materials described.

Abstract: A medical system comprising a compressible device, and a covering over the compressible device, wherein the covering includes a delivery configuration and a deployed configuration, wherein, in the delivery configuration, the covering at least partially covers the compressible device to maintain the compressible device in a compressed state, and wherein, in the deployed configuration, the covering is releasable from the device to transition the compressible device from the compressed state to an expanded state.

Abstract: The invention is a wearable breast pump system including a housing shaped at least in part to fit inside a bra and a piezo air-pump. The piezo air-pump is fitted in the housing and forms part of a closed loop system that drives a separate, deformable diaphragm to generate negative air pressure. The diaphragm is removably mounted on a breast shield.